Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma

Shao, Yu‐Yun; Chen, Pai‐Sheng; Lin, Liang-In; Lee, Bin-Shyun; Ling, Andrew; Cheng, Ann‐Lii; Hsu, Chiun; Ou, Da-Liang

doi:10.1038/s41416-022-01759-w

Cited by 12 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In preclinical models, sorafenib induced miR-10b-3p extrusion, and higher miR-10b-3p levels were associated with sorafenib sensitization, leading authors to hypothesize its possible use as a biomarker for patients treated with sorafenib. In a small patient cohort, higher miR-10b-3p serum levels predicted a better OS but not progression-free survival when analyzed before treatment [123]. Interestingly, miR-10b is overexpressed in several tumors including HCC, and its expression in the exosomal fraction from early-HCC patients is closely associated with tumor size and recurrence, representing an independent prognostic factor for poor survival [124].…”

Section: Noncoding Rnas As Biomarkers Of Treatment Response In Hccmentioning

confidence: 99%

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response

Vianello,

Monti,

Leoni

et al. 2024

Cancers

View full text Add to dashboard Cite

The incidence of hepatocellular carcinoma (HCC) is increasing, and 40% of patients are diagnosed at advanced stages. Over the past 5 years, the number of clinically available treatments has dramatically increased for HCC, making patient management particularly complex. Immune checkpoint inhibitors (ICIs) have improved the overall survival of patients, showing a durable treatment benefit over time and a different response pattern with respect to tyrosine kinase inhibitors (TKIs). Although there is improved survival in responder cases, a sizeable group of patients are primary progressors or are ineligible for immunotherapy. Indeed, patients with nonviral etiologies, such as nonalcoholic steatohepatitis (NASH), and alterations in specific driver genes might be less responsive to immunotherapy. Therefore, improving the comprehension of mechanisms of drug resistance and identifying biomarkers that are informative of the best treatment approach are required actions to improve patient survival. Abundant evidence indicates that noncoding RNAs (ncRNAs) are pivotal players in cancer. Molecular mechanisms through which ncRNAs exert their effects in cancer progression and drug resistance have been widely investigated. Nevertheless, there are no studies summarizing the synergistic effect between ncRNA-based strategies and TKIs or ICIs in the preclinical setting. This review aims to provide up-to-date information regarding the possible use of ncRNAs as therapeutic targets in association with molecular-targeted agents and immunotherapies and as predictive tools for the selection of optimized treatment options in advanced HCCs.

show abstract

Section: Noncoding Rnas As Biomarkers Of Treatment Response In Hccmentioning

confidence: 99%

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response

Vianello,

Monti,

Leoni

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…However, there are still no considerable biomarkers to predict the treatment efficacy. It has been shown that low miR-10b-3p level is associated with sorafenib resistance in HCC ( Shao et al, 2022 ). Exosomal miR-30d is highly expressed in the sorafenib effective patients and thereby maybe serve as a predictive biomarker for the efficacy of sorafenib in HCC ( Kohno et al, 2020 ) .…”

Section: Exosomes In Hcc Diagnosis and Prognosismentioning

confidence: 99%

Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine

Yao

Liang²,

Cheng³

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) usually occurs on the basis of chronic liver inflammatory diseases and cirrhosis. The liver microenvironment plays a vital role in the tumor initiation and progression. Exosomes, which are nanometer-sized membrane vesicles are secreted by a number of cell types. Exosomes carry multiple proteins, DNAs and various forms of RNA, and are mediators of cell-cell communication and regulate the tumor microenvironment. In the recent decade, many studies have demonstrated that exosomes are involved in the communication between HCC cells and the stromal cells, including endothelial cells, macrophages, hepatic stellate cells and the immune cells, and serve as a regulator in the tumor proliferation and metastasis, immune evasion and immunotherapy. In addition, exosomes can also be used for the diagnosis and treatment HCC. They can potentially serve as specific biomarkers for early diagnosis and drug delivery vehicles of HCC. Chinese herbal medicine, which is widely used in the prevention and treatment of HCC in China, may regulate the release of exosomes and exosomes-mediated intercellular communication. In this review, we summarized the latest progresses on the role of the exosomes in the initiation, progression and treatment of HCC and the potential value of Traditional Chinese medicine in exosomes-mediated biological behaviors of HCC.

show abstract

“…Xu et al 11 described the low expression level of miR‐541 in HCC and the consequent enhanced response of HCC to Sor treatment by inhibiting autophagy. Shao et al reported that miR‐10b‐3p overexpression can promote HCC cell apoptosis and that high miR‐10b‐3p serum levels could be a biomarker to predict the efficacy of Sor treatment in patients with advanced HCC 12 . There is an abundance of information about miR‐224 function in HCC progression; considering its elevated expression in liver tissue, miR‐224 is regarded as an oncogene because it promotes HCC progression 13 .…”

Section: Introductionmentioning

confidence: 99%

“…Shao et al reported that miR-10b-3p overexpression can promote HCC cell apoptosis and that high miR-10b-3p serum levels could be a biomarker to predict the efficacy of Sor treatment in patients with advanced HCC. 12 There is an abundance of information about miR-224 function in HCC progression; considering its elevated expression in liver tissue, miR-224 is regarded as an oncogene because it promotes HCC progression. 13 However, whether the combination of Rop and Sor inhibits HCC cell proliferation and metastasis via miR-224 and its target mRNA remains unclear.…”

mentioning

confidence: 99%

Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR‐224/HOXD10 axis

Wang,

Lin

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

ObjectiveThe development of drug resistance in hepatocellular carcinoma (HCC) cells limits the effectiveness of sorafenib (Sor). However, the regulatory mechanisms underlying the effects of the combination Sor and ropivacaine (Rop) on HCC cells remain unclear.MethodsmiR‐224 and HOXD10 mRNA expression in HCC cells was analyzed using qRT‐PCR. CCK‐8, Transwell assays and tumor formation experiments in nude mice were used to assess HCC cell proliferation, migration, and invasion. Migration of HCC cells was also analyzed using a cell scratch assay. Hematoxylin and eosin staining was used to detect tumor area.ResultsmiR‐224 expression profoundly increased in HepG2 and Huh7 cells. Treatment with Rop and/or Sor blocked miR‐244 expression, especially the combination treatment. Transfection of miR‐224 mimic increased HCC cell proliferation and tumor size in nude mice, and migration and invasion in vitro in the presence of Rop and Sor compared to the negative control mimic. Dual‐luciferase reporter assays showed that HOXD10 was targeted by miR‐224. HOXD10 protein expression and was markedly reduced in HepG2 and Huh7 cells. Rop and/or Sor treatment increased HOXD10 protein expression, particularly the combination treatment. miR‐224 negatively regulated HOXD10 expression in HCC cells treated with Rop and Sor. Transfection‐mediated silencing of HOXD10 increased HCC cell proliferation, migration, and invasion in the presence of Rop and Sor compared with negative control transfection.ConclusionThe combination of Rop and Sor attenuates HCC cell proliferation and metastasis via the miR‐224/HOXD10 axis.

show abstract

Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma

Cited by 12 publications

References 49 publications

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response

Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response

Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine

Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR‐224/HOXD10 axis

Contact Info

Product

Resources

About